NCT07353957

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer in Combination With Pembrolizumab as First-Line Treatment

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Merus B.V. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.

Conditions

• Lung Cancer - Non Small Cell Squamous
• Lung Cancer - Non Small Cell Non-Squamous

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Petosemtamab + Pembrolizumab	Petosemtamab + Pembrolizumab

Timeline

• Start date: 2025-03-27
• Primary completion: 2028-05-31
• Completion: 2031-02-27
• First posted: 2026-01-21
• Last updated: 2026-04-02

Locations

5 sites across 2 countries: United States, Australia

Regulatory

• FDA-regulated drug study